Navigation Links
Researchers study new drug and indications for heated chemotherapy treatment
Date:3/14/2008

WINSTON-SALEM, N.C. Studies have shown that surgery combined with Intraperitoneal Hyperthermic Chemotherapy (IPHC) can improve survival rates for select patients with peritoneal carcinoma (cancer of the lining of the abdominal cavity) that has spread from colorectal or appendix cancer.

Researchers from Wake Forest University School of Medicine will present findings from two studies on the use of IPHC in treating peritoneal cancer that has spread from these two primary cancer sites at the annual meeting of the Society of Surgical Oncology in Chicago, March 13-16.

John H. Stewart, IV, M.D., assistant professor of surgery, section of surgical oncology, reports March 13 on the results of a study evaluating toxicity when combining surgery and IPHC using oxaliplatin as the chemotherapy agent in patients with peritoneal cancer which originated as colorectal or appendix cancer.

A large body of literature suggests that oxaliplatin is superior to other chemotherapy agents in killing colorectal cancer cells, said Stewart. Further, we have previously demonstrated that the cancer-killing effects of oxaliplatin are increased when the agent is heated during perfusion.

The purpose of the phase I study was to establish the maximum tolerated dose of oxaliplatin used in IPHC treating colorectal and appendix cancers that have spread to the peritoneum.

Fifteen patients were enrolled in the study at two dose levels, 200 mg/m and 250 mg/m. At the maximum tolerated dose of 200 mg/m, only two significant toxicities were encountered. More severe toxicities were observed in patients receiving 250 mg/m.

Researchers concluded that IPHC with 200 mg/m of oxaliplatin is well tolerated and is the maximally tolerated dose for a two-hour chemoperfusion.

Based on the data from this phase I study, we propose to conduct a larger trial with oxaliplatin dose to study its efficacy in improving outcomes in patients with peritoneal carcinoma, said Stewart.

On March 14, Perry Shen, M.D. associate professor, section of surgical oncology, will report findings on the use of IPHC in patients with peritoneal cancer and hepatic metastases (HM), or liver cancer that has metastasized from colorectal cancer. The use of IPHC in patients with this presentation is controversial.

This was a retrospective study of 144 patients undergoing surgery to remove as much of the cancer as possible and IPHC between 1991 and 2007, said Shen. There were 17 patients with HM. Clinical and pathological information was obtained from a prospectively collected database and electronic medical record.

Median overall survival for patients with and without HM was 22.7 months and 15.8 months respectively, which was not a significant difference. Two- and four-year survival rates for the HM patients were 34.0 percent and 11.3 percent. Further analysis demonstrated the presence of malignant fluid in the abdominal cavity to be a significant predictor of decreased survival in patients with HM.

We concluded that patients with peritoneal carcinoma and hepatic metastases undergoing cytoreductive surgery and IPHC for colorectal cancer had no significant difference in overall survival compared to those without HM, said Shen. In select patients with peritoneal carcinoma and hepatic metastases, cytoreductive surgery and IPHC may have some benefit. Malignant ascites, an accumulation of fluid in the peritoneal cavity, predicted a poor outcome.


'/>"/>

Contact: Jonnie Rohrer
jrorher@wfubmc.edu
336-716-6972
Wake Forest University Baptist Medical Center
Source:Eurekalert

Related medicine news :

1. Researchers use light to detect Alzheimers
2. Penn researchers identify first sex chromosome gene involved in meiosis and male infertility
3. Mayo Researchers Say ECG Standards Should Be Revised for Elderly
4. Mayo researchers say ECG standards should be revised for elderly
5. Researchers confirm link between common cold and ear infection
6. Researchers make case for standardized analysis of cardiac imaging
7. Researchers find cause of severe allergic reaction to cancer drug
8. Researchers develop a method to select eggs with the best chance of leading to successful pregnancy
9. USC researchers find benefit for lymphoma patients in combined PET-CT scanning
10. Researchers ID behavioral risk factors for head and neck cancers
11. Red-light cameras increase crashes, researchers find
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/26/2016)... ... ... PawPaws brand pet supplements owned by Whole Health Supply is ... of felines. The formula is all-natural and is made from Chinese herbs that have ... Kidney Support Supplement Soft Chews are Astragalus Root Extract and Rehmannia Root Extract ...
(Date:6/25/2016)... ... 2016 , ... Experts from the American Institutes for Research ... June 26-28, 2016, at the Hynes Convention Center in Boston. , AIR experts ... planning, healthcare costs and patient and family engagement. , AIR researchers will be ...
(Date:6/25/2016)... Viejo, California (PRWEB) , ... June 25, 2016 , ... ... to fit their specific project," said Christina Austin - CEO of Pixel Film Studios. ... fully customizable and all within Final Cut Pro X . Simply select a ...
(Date:6/25/2016)... , ... June 25, 2016 , ... ... and non-athletes recover from injury. Recently, he has implemented orthobiologic procedures as a ... area —Johnson is one of the first doctors to perform the treatment. Orthobiologics ...
(Date:6/24/2016)... ... June 24, 2016 , ... A recent article published June ... with. The article goes on to state that individuals are now more comfortable seeking ... common operations such as calf and cheek reduction. The Los Angeles area medical group, ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... 2016 Any dentist who has made an implant ... process. Many of them do not even offer this as ... high laboratory costs involved. And those who ARE able to ... a high cost that the majority of today,s patients would ... Parsa Zadeh , founder of Dental Evolutions Inc. and inventor ...
(Date:6/23/2016)... LOS ANGELES , June 23, 2016 /PRNewswire/ ... (NASDAQ: CAPR ), a biotechnology company ... first-in-class therapeutics, today announced that patient enrollment in ... progrEssion in Duchenne) has exceeded 50% of its ... its enrollment in the third quarter of 2016, ...
(Date:6/23/2016)... 2016  Astellas today announced the establishment of Astellas Farma Colombia (AFC), a new affiliate with operations headquartered in ... America . ... ... ... ...
Breaking Medicine Technology: